Alchemix V3 vs Metronome Synth: Which fits your strategy? (2026)

Alchemix V3 and Metronome Synth both sit in DeFi synthetics, but they serve different jobs. Alchemix centers on borrowing against ETH or USDC while collateral continues earning yield. Its advertised loan interest is 0%, and the protocol also offers fixed-date Transmuter redemptions and a portfolio of DAO-curated yield strategies. Metronome Synth instead lets users post crypto collateral to mint msUSD, msETH and msBTC, synthetic assets that track USD, ETH and BTC prices.

Choose Alchemix if you want a loan or yield product and are comfortable with repayment depending on strategy performance. Choose Metronome if your main goal is synthetic exposure to several major assets. Alchemix also supports Arbitrum, which Metronome does not list. Both operate on Ethereum, Optimism and Base.

Alchemix advertises 0% interest on loans, but that does not mean every action is cost-free. It does not publish other protocol charges for yield, redemptions or strategy management. Metronome Synth does not publish fees for minting, swaps, liquidations, borrowing or stability charges. For both protocols, network gas applies when users make on-chain transactions, and gas costs vary by chain and congestion.

If predictable costs are important, neither protocol gives a complete public fee picture in these details. Alchemix at least states its loan interest rate; Metronome's protocol fees are not published. Check the app and documentation for the costs that apply to a specific transaction before committing collateral or minting assets. Do not treat the advertised 0% interest as proof that an Alchemix position has no other costs.

Alchemix lists two audits, and its homepage points to open-source code and risk controls. The project does not name the auditors or publish the audits' scope and findings here. Its main stated risks include smart-contract faults, poor performance in underlying yield strategies and alAsset de-pegging. Because loan repayment depends on yield, lower or halted yield can slow or stop self-repayment. V3 is also new, so its track record is short.

Metronome Synth lists no audits. Its risks include smart-contract faults, oracle problems, LayerZero cross-chain messaging failures and liquidation if collateral falls in value. Neither protocol's audit status should be treated as a safety guarantee. Alchemix's claim of no market liquidation risk is limited to market-price liquidations; it does not remove smart-contract, strategy or peg risks. Use caution with collateral you cannot afford to lose.

Alchemix combines an Alchemist loan system, Transmuter redemptions, MYT yield strategies and an earmarking mechanism. That gives users several ways to engage, including lower-LTV options, but the parts can be harder to understand than a basic lending market. Its 90% LTV ceiling is tied to the new redemption design, and details on handling liquidation or peg stress are limited. The protocol lists four chains.

Metronome's main path is more direct in concept: post crypto collateral, then mint one of its synthetic assets. Its tokens are described as LayerZero OFTs for multichain minting, and the protocol lists three chains. However, collateral ratios, liquidation penalties and fees are not published, so users need to investigate those mechanics before opening a position. Metronome's listed TVL is about $10.3 million, while its homepage reports about $21.4 million; verify the current figure before relying on it.

Pick Alchemix V3 if you want a self-repaying loan against ETH or USDC, value the advertised 0% interest, or want fixed-date yield and redemption features. It is also the only one of these protocols that lists Arbitrum support. Its trade-offs are a more complex design, repayment tied to strategy yield, and a short V3 track record. Two audits are listed, but their auditors and findings are not public.

Pick Metronome Synth if you specifically want to mint synthetic USD, ETH or BTC exposure against crypto collateral. It supports multichain tokens across Ethereum, Optimism and Base and has MET governance. Its key drawbacks are that no audits are listed and fee, collateral-ratio and liquidation-penalty details are not published. If you cannot evaluate those risks without clearer disclosures, do not open a position until you have the details you need.